Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1Approved for marketing 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 1Expanded_access 1

Sponsor

Cancer Type

Plasma cell 15Genitourinary 14Lymphoid 6Other hematologic neoplasm 4Gastrointestinal 3Breast 3Thoracic 2Sarcoma 2Other 2Classical hematology 2Myeloid 1Head & Neck 1Gynecologic 1

Conditions

Sarcoma 960Glioblastoma 299Gliosarcoma 288Osteosarcoma 286Brain Neoplasms 195Dendritic Cell Sarcoma, Interdigitating 188Gastrointestinal Stromal Tumors 180Bone Neoplasms 172Lymphoma 161Central Nervous System Neoplasms 160Astrocytoma 155Sarcoma, Ewing 151Glioma 149Precursor Cell Lymphoblastic Leukemia-Lymphoma 147Lymphoma, Non-Hodgkin 143Burkitt Lymphoma 139Neoplasms 137Recurrence 134Lymphoma, Large B-Cell, Diffuse 128Lymphoma, Follicular 128Rhabdomyosarcoma 126Neuroblastoma 126Hodgkin Disease 124Oligodendroglioma 123Breast Neoplasms 123Lymphoma, Mantle-Cell 117Leukemia, Myeloid, Acute 117Leukemia, Lymphocytic, Chronic, B-Cell 117Lymphoma, B-Cell, Marginal Zone 113Leukemia 111

Interventions

glucarpidase 2gamma-Glutamyl Hydrolase 1Methotrexate 1Leucovorin 1Carboxypeptidases 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Renal Insufficiency × Sarcoma × Clear all
NCT00634504 2022-06-06

LVPK

BTG International Inc.

Phase 1 Completed
20 enrolled 9 charts
LymphoidOther hematologic neoplasmSarcoma

Leukemia, Lymphoma, Osteosarcoma, Renal Insufficiency

NCT00481559 2014-01-17

Treatment Protocol of Voraxaze for Patients Experiencing or at Risk of Methotrexate Toxicity

BTG International Inc.

Approved for marketing
LymphoidOther hematologic neoplasmSarcoma

Leukemia, Lymphoma, Neoplasms, Osteosarcoma, Renal Insufficiency

Data powered by HemOnc (CC BY 4.0) Colophon âš¡